Phreesia, Inc. (NYSE:PHR – Get Free Report) COO Evan Roberts sold 1,785 shares of Phreesia stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $26.98, for a total value of $48,159.30. Following the sale, the chief operating officer now directly owns 768,208 shares in the company, valued at $20,726,251.84. This trade represents a 0.23 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Evan Roberts also recently made the following trade(s):
- On Wednesday, January 8th, Evan Roberts sold 2,681 shares of Phreesia stock. The shares were sold at an average price of $27.95, for a total transaction of $74,933.95.
- On Monday, January 6th, Evan Roberts sold 2,873 shares of Phreesia stock. The shares were sold at an average price of $26.61, for a total transaction of $76,450.53.
Phreesia Stock Up 1.6 %
PHR traded up $0.44 on Friday, hitting $27.24. The company had a trading volume of 309,924 shares, compared to its average volume of 382,284. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of -18.53 and a beta of 0.94. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. The stock has a fifty day moving average price of $23.42 and a 200-day moving average price of $22.77. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $29.16.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price target on shares of Phreesia in a research note on Friday, January 10th. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and raised their price objective for the stock from $24.00 to $32.00 in a research note on Wednesday, January 8th. KeyCorp upped their target price on Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Wednesday, January 8th. Citigroup raised their price target on Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $30.00 price objective on shares of Phreesia in a research report on Tuesday, December 10th. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $31.00.
Check Out Our Latest Report on Phreesia
Institutional Investors Weigh In On Phreesia
A number of large investors have recently made changes to their positions in the stock. International Assets Investment Management LLC raised its stake in shares of Phreesia by 2,179.7% in the third quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock worth $33,000 after purchasing an additional 1,395 shares during the last quarter. Lombard Odier Asset Management USA Corp purchased a new stake in shares of Phreesia in the 2nd quarter valued at $202,000. Point72 DIFC Ltd purchased a new position in shares of Phreesia during the second quarter worth $209,000. XTX Topco Ltd acquired a new position in Phreesia during the third quarter valued at $247,000. Finally, Hsbc Holdings PLC purchased a new stake in Phreesia in the second quarter valued at $301,000. 92.10% of the stock is owned by hedge funds and other institutional investors.
About Phreesia
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
See Also
- Five stocks we like better than Phreesia
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- How to invest in marijuana stocks in 7 steps
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- How Investors Can Find the Best Cheap Dividend Stocks
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.